Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Syndax Pharmaceuticals (SNDX) Receivables - Net (2024 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Receivables - Net for 3 consecutive years, with $38.1 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables - Net rose 142.44% year-over-year to $38.1 million; the TTM value through Mar 2026 reached $38.1 million, up 142.44%, while the annual FY2025 figure was $38.0 million, 399.82% up from the prior year.
  • Receivables - Net hit $38.1 million in Q1 2026 for Syndax Pharmaceuticals, roughly flat from $38.0 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $38.1 million in Q1 2026 and bottomed at $7.6 million in Q4 2024.
  • Average Receivables - Net over 3 years is $24.0 million, with a median of $22.4 million recorded in 2025.
  • Year-over-year, Receivables - Net skyrocketed 399.82% in 2025 and then skyrocketed 142.44% in 2026.
  • Syndax Pharmaceuticals' Receivables - Net stood at $7.6 million in 2024, then surged by 399.82% to $38.0 million in 2025, then grew by 0.32% to $38.1 million in 2026.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $38.1 million, $38.0 million, and $25.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.